Davis J. E. sold $1.9M of DGX

Davis J. E. (CEO and President) sold 10,000 shares of QUEST DIAGNOSTICS INC (DGX) at $194.14 ($1.94M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Davis J. E.
Published Jun 2, 2026, 10:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 2, 2026, 10:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DGX
Neutral
medium confidence
Mentioned
$DGX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DGXNeutralLow
01

Why it matters

The disclosure may influence short-term sentiment among traders who track insider flows, but the 10b5-1 designation generally lowers the probability of a fundamental read-through.

02

Market read

A disclosed insider sale in DGX; likely more relevant for sentiment/positioning than for fundamentals.

03

What to watch

The filing does not indicate whether additional tranches remain under the same 10b5-1 plan, nor does it provide context on the executive’s broader compensation/hedging activity.

Relevance 6/10Novelty 6/10Timing: Filed after-hours on 2026-06-02; reflects sale executed 2026-06-01.

Background

SEC Form 4 reports insider transactions; this one is an open-market sale by the CEO/President under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$DGXNeutralMedium confidence
Context

Quest Diagnostics CEO and President Davis J. E. sold 10,000 shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any impact is more likely short-term and sentiment-driven.

Evidence & confidence

The filing is a routine insider disclosure and explicitly states a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary sales.

Market effects

Minimal; this is company-specific insider activity with no stated operational/regulatory catalyst.

None indicated.

None indicated.

Counterpoint

10b5-1 sales can be purely mechanical; the sale may not reflect bearish fundamentals and could be offset by other insider buys or institutional activity not shown here.

Key entities

  • Quest Diagnostics Inc

    DGX, the company whose shares were sold by its CEO/President.

  • Davis J. E.

    CEO and President who executed the sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DGXLow

Quest Diagnostics Pays $13 Million to Settle Kickback Allegations Involving New York Giants Tickets

Quest Diagnostics will pay $13M to settle allegations of illegal kickbacks, including New York Giants tickets, to healthcare providers. The U.S. Attorney's Office claims the company violated the Anti-Kickback Statute from 2013 to 2022, offering perks in exchange for business referrals. Quest denies wrongdoing but agreed to a settlement and a 5-year compliance agreement.

$DGXLow

Quest Diagnostics pays more than $13M to settle alleged kickback scheme, federal prosecutors say

Quest Diagnostics agreed to pay $13M to settle allegations of a kickback scheme involving gifts to hospital executives, including New York Giants game tickets, according to federal prosecutors. The scheme allegedly lasted from 2013 to 2022, with Quest billing government-funded medical plans. The company will also face five years of auditing. Quest reported $11B in 2025 revenue, up 7%.

$DGXLow

Quest Diagnostics pays $13M to settle kickback allegations involving NY Giants tickets

Quest Diagnostics agreed to pay $13M to settle allegations of providing illegal kickbacks, including NY Giants tickets, to healthcare providers for referrals, according to the U.S. Attorney’s Office of New Jersey. The settlement resolves claims of violating the Anti-Kickback Statute and submitting false claims to Medicare and Medicaid. Quest denies wrongdoing but agreed to the settlement to resolve the matter.

$DGXLow

Quest Diagnostics pays more than $13 million to settle allegations of illegal kickbacks involving Giants tickets, VIP events

Quest Diagnostics Inc. paid $13,014,576 plus interest to settle federal allegations of illegal kickbacks involving free New York Giants tickets and VIP events to induce patient referrals. The company violated the Anti-Kickback Statute and submitted false claims to Medicare and Medicaid programs, according to the U.S. Attorney’s Office. Quest also entered a five-year Corporate Integrity Agreement with HHS-OIG. Whistleblowers will receive nearly $2.5 million.

$LHMed

Labcorp, Quest urge RESULTS Act passage as lab payment cuts loom

Labcorp and Quest Diagnostics warn of revenue impacts from upcoming Medicare and Medicaid reimbursement cuts starting in 2027. Labcorp expects a $125 million hit, while Quest estimates a 1% revenue reduction in 2026. Both companies advocate for the passage of the RESULTS Act to reform the payment rate-setting process, citing concerns over patient access and lab viability.